(For further details, see Arrhythmias → Tachyarrhythmias → Ventricular Tachycardia)
As outlined in the relevant chapter, ventricular tachycardias are classified into three major categories based on their underlying etiology:
- Ventricular tachycardia in patients with structural heart disease
- Ventricular tachycardia in patients without apparent structural heart disease or idiopathic ventricular tachycardia
- Ventricular tachycardia in patients with inherited arrhythmia syndromes
Ventricular Tachycardia Ablation in Patients with Structural Heart Disease
Myocardial fibrosis present in patients with structural heart disease is responsible for forming reentry circuits that generate ventricular tachycardias. Ventricular tachycardias in this patient cohort represent a life-threatening event that can lead to death. Consequently, the primary therapeutic measure is the implantation of a cardioverter-defibrillator (ICD) to prevent such an outcome. Although an ICD successfully terminates ventricular tachycardia episodes, it has no preventive effect on their recurrence. Prevention is achieved via pharmacological therapy and catheter ablation.
Patient Selection and Indications for Ablation
Ventricular tachycardia ablation is an effective technique, but its success rates are lower than those of supraventricular tachycardias, which approach 100%. Given the clinical severity of the episodes and the potential for recurrence, ablation cannot serve as the sole treatment modality in the vast majority of cases. Typically, the patient is protected from the risk of arrhythmic sudden cardiac death through ICD implantation, while pharmacological therapy is concurrently administered for episode prevention.
Generally, catheter ablation is indicated for the following patient categories:
- Patients with multiple, symptomatic episodes of ventricular tachycardia despite optimal pharmacological therapy: In patients with an implanted ICD, ventricular tachycardia episodes may be perceived when an electrical shock is delivered by the device or identified during routine device interrogation. Generally, patients experiencing more than 3–4 episodes within their 6-month follow-up intervals, despite optimal medical therapy, are candidates for ablation. However, this approach is individualized and depends on the patient’s profile, symptom severity, and alternative therapeutic options (e.g., up-titrating pharmacological therapy, reprogramming the ICD to deliver antitachycardia pacing to avoid shocks).
- Patients presenting with electrical storm: Electrical storm is defined as a clinical state where a patient experiences more than 3 episodes of ventricular tachycardia within a 24-hour period, requiring corresponding therapies from the ICD. This is an acute medical emergency requiring hospitalization and specialized treatment, which may include catheter ablation.
- Symptomatic patients with ventricular tachycardia episodes who decline pharmacological therapy.
- Patients in whom previously effective pharmacological therapy has induced severe adverse effects: Amiodarone, the most potent antiarrhythmic drug for preventing ventricular tachycardia recurrences, is associated with numerous adverse effects (thyroid dysfunction, pulmonary toxicity, hepatic impairment, ocular disturbances, etc.).
- Patients with highly frequent episodes or incessant ventricular tachycardia prior to ICD implantation: In this clinical scenario, ablation must be performed first to terminate the tachycardia and suppress recurrent episodes. Implanting an ICD first would otherwise lead to repetitive, continuous device discharges.
- Patients who decline ICD implantation: This scenario falls outside standard guideline-recommended indications, as ablation alone does not provide absolute protection against sudden death.
Procedural Objectives
The primary objective of the procedure is to decrease ventricular tachycardia episodes and reduce the overall arrhythmic burden. During the procedure, detailed electroanatomical mapping of the cardiac ventricles is performed to identify and reconstruct within 3D mapping systems the specific regions responsible for sustaining the reentry circuits. Ablation therapy is delivered precisely to these areas. The target is the elimination of abnormal potentials and the application of energy across all arrhythmogenic substrates.
Upon completion of the ablation, programmed ventricular stimulation is performed to reinduce ventricular tachycardia. If no ventricular tachycardia can be induced, the procedural outcome is considered fully successful. A highly favorable ablation outcome is achieved when the clinical tachycardia observed pre-operatively is no longer inducible, even if other, non-clinical morphologic forms of ventricular tachycardia are induced. This indicates that while the pathological substrate generating the baseline clinical tachycardia has been eliminated, an alternate substrate capable of producing different ventricular tachycardia morphologies remains. Although these alternate morphologies rarely manifest spontaneously in clinical practice, there is always a longitudinal risk of future ventricular tachycardia episodes, as the underlying disease persists and the arrhythmogenic substrate cannot be completely eradicated.
Pre-Procedural Patient Preparation
Pre-operative preparation is summarized as follows:
- If the patient is on oral anticoagulants, peri-procedural management must be coordinated with the physician.
- Antiarrhythmic medications do not routinely need to be discontinued, and the baseline pharmacological regimen is maintained.
- The patient must be in a stable hemodynamic and clinical state regarding their underlying cardiac disease (e.g., heart failure optimization).
- A pre-operative transthoracic echocardiogram is mandatory to provide a clear assessment of structural abnormalities and cardiac function, delineate aortic valve morphology and patency, and rule out left ventricular thrombus. The presence of severe aortic valve stenosis and calcification, or a left ventricular thrombus, constitutes a contraindication for the procedure.
- The patient must fast on the morning of the procedure, though a standard evening meal the night before is permissible.
- Upon admission, the patient must provide prior diagnostic test results and detailed medical history records.
Procedural Technique
The procedure is typically performed under local anesthesia at the vascular access sites without general anesthesia. However, if the procedure is not well tolerated, deep sedation is utilized.
In the electrophysiology laboratory, the patient is placed under continuous electrocardiographic monitoring. Following local anesthesia, percutaneous punctures are performed in the femoral region to introduce specialized vascular sheaths into the femoral veins. Through these sheaths, electrophysiology catheters (multipolar electrodes) are advanced and positioned at specific sites within the cardiac chambers. Concurrently, a steerable ablation catheter capable of both mapping and energy delivery is introduced. If the tachycardia originates in the left ventricle (which represents the majority of cases), the ablation catheter is introduced retrogradely via the femoral artery and guided through the aorta into the left ventricular cavity. An alternative transseptal approach to the left ventricle may be utilized, involving an interatrial septal puncture via femoral venous access.
Intracardiac electrograms are recorded via the catheters and displayed on the laboratory mapping systems. Ventricular tachycardia ablations utilize a 3D electroanatomical mapping system, allowing real-time visualization and navigation of the catheters without continuous fluoroscopy. The 3D system also facilitates the creation of a high-density anatomical and voltage map of the heart, highlighting regions of myocardial fibrosis characterized by low electrical voltage. Furthermore, the activation sequence of the electrical impulse during ventricular tachycardia can be recorded.
During the electrophysiological study, ventricular tachycardia is induced via programmed stimulation. If hemodynamically tolerated, activation and entrainment mapping are attempted. If the tachycardia is poorly tolerated and causes hemodynamic instability, substrate mapping of the pathological regions is conducted during baseline normal sinus rhythm. Subsequently, ablation is targeted at the critical components of the substrate.
Occasionally, mapping and ablation of the epicardial surface of the heart are required. Epicardial access is achieved via a subxiphoid pericardial puncture to introduce the ablation catheter into the pericardial space. Epicardial ablation is a specialized and highly valuable technique that permits the neutralization of arrhythmogenic foci and reentry circuits located deep within the myocardium or exclusively on the outer surface of the heart. These regions cannot be adequately accessed or heated via the standard endocardial approach from within the cardiac chambers. This method is primarily essential for patients with non-ischemic cardiomyopathies (such as dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy) and in cases where a previous endocardial ablation failed to control the arrhythmia. Utilizing 3D mapping systems, the operator can accurately localize the epicardial pathological substrate, offering a definitive therapeutic solution and significantly increasing overall procedural success rates in complex cases.
The introduction of Pulsed Field Ablation (PFA) in recent years, which is now applied to ventricular tachycardia, has contributed significantly to achieving superior therapeutic outcomes.
Following the delivery of ablation lesions, re-evaluation via programmed stimulation is performed to reinduce the index or alternative ventricular tachycardias. If no tachycardia is inducible, the procedure is completed and deemed highly successful. If tachycardia remains inducible, supplementary ablation lesions are delivered until the final endpoint of non-inducibility is achieved, or at least until the clinical morphology responsible for the multiple clinical episodes is suppressed. Following this, the catheters are withdrawn, hemostasis is achieved at the puncture sites, and the patient is transferred to the recovery holding area before returning to the inpatient ward.
Post-Procedural Care
Immediately post-procedure, the patient returns to the ward, where they remain on strict bed rest, ensuring no vigorous movement of the lower extremities during the initial hours. Mobilization can occur later the same day or the following morning. Next-morning evaluation includes a 12-lead electrocardiogram, after which the patient receives discharge instructions and leaves the hospital. The patient may resume normal physical activities on the second post-operative day. If the patient carries an ICD, regular device interrogation is required per medical instructions to monitor for potential ventricular tachycardia recurrences.
Expected Outcomes
The expected outcome of the procedure, achieved in over 80% of cases, is a significant reduction in ventricular tachycardia burden and a corresponding decrease in ICD therapies (primarily electrical shocks). Multiple ICD shocks delivered for ventricular tachycardias, besides being a distressing experience for the patient, carry an adverse prognostic implication. Repetitive electrical shocks may further impair an already vulnerable myocardium. Consequently, reducing ventricular tachycardia episodes via ablation exerts beneficial clinical effects. Post-ablation, antiarrhythmic pharmacological therapy may be adjusted or maintained to further optimize the prevention of recurrences.
Risks and Complications
Ventricular tachycardia ablation in the setting of structural heart disease is a complex and demanding intervention that should be restricted to high-volume centers with specialized expertise. The overall complication rate ranges between 5% and 8%. The primary complications include:
- Hematoma at the vascular access sites (3–5%): In most instances, hematomas resorb spontaneously within a few days. Severe cases, such as retroperitoneal hematoma, have been reported rarely.
- Conduction system impairment (~1%): This may include left bundle branch block (LBBB) or atrioventricular (AV) block. Usually, these patients have baseline backup pacing from an implanted pacemaker/ICD, mitigating immediate clinical risk. If the induced conduction delay causes cardiac dyssynchrony, subsequent upgrade to a biventricular cardiac resynchronization therapy (CRT) system may be indicated.
- Cardiac tamponade (~0.5–1%): Cardiac tamponade is defined as the escape of blood from the cardiac chambers and its accumulation within the pericardial space (the sac surrounding the heart). It represents an acute medical emergency requiring immediate pericardiocentesis to aspirate the accumulated blood. This intervention is typically definitive. A small indwelling drainage catheter remains in the pericardial space for approximately 24 hours and is subsequently removed under close clinical monitoring. This complication usually extends hospital stay by 2–4 days.
- Thromboembolic events (<1%).
- Aortic valve or coronary artery injury due to catheter manipulation (sporadic case reports).
- Mortality: Deaths have been reported in certain patient series. However, these are highly correlated with the baseline severity and comorbidities of the patient cohort. Ventricular tachycardia often represents the terminal event in the natural history of end-stage heart failure. It is highly probable that a significant proportion of recorded moralities involved end-stage patients. Such severe complications are not typically reported in patient cohorts where ablation was performed at earlier stages of the underlying disease continuum. Consequently, the incidence of major complications is heavily dependent on patient selection.
Idiopathic Ventricular Tachycardia Ablation
To classify a ventricular tachycardia as idiopathic, structural heart disease must be definitively excluded via comprehensive cardiovascular evaluation. Consequently, patients with idiopathic ventricular tachycardia possess an otherwise structurally normal heart.
Patient Selection and Indications for Ablation
Catheter ablation is indicated for the following patient categories:
- Patients experiencing one or more symptomatic episodes of ventricular tachycardia despite pharmacological therapy.
- Patients with one or more episodes of ventricular tachycardia who decline long-term pharmacological therapy.
- Patients in whom antiarrhythmic drug therapy has induced adverse effects: Amiodarone, the most effective drug for preventing ventricular tachycardia episodes, is associated with significant long-term toxicities (thyroid disease, pulmonary fibrosis, hepatotoxicity, corneal microdeposits, etc.). Consequently, amiodarone is not a first-line treatment option when the ventricular tachycardia can be definitively cured with catheter ablation.
- Asymptomatic patients with a high ventricular arrhythmic burden who exhibit evidence of deteriorating ventricular function secondary to the arrhythmia (tachycardia-induced cardiomyopathy).
Procedural Objectives
The objective of the procedure is the localized ablation (thermal elimination) of the arrhythmogenic focus generating the ventricular tachycardia. The anatomical location of the focus within the heart can be predicted pre-operatively based on the 12-lead electrocardiographic morphology during tachycardia. However, definitive localization is achieved via high-density intraoperative mapping, followed by targeted energy delivery. A fully successful outcome is defined as the complete eradication of any arrhythmia originating from that specific focus.
Occasionally, during electroanatomical mapping in patients previously diagnosed with idiopathic ventricular tachycardia, localized areas of low electrical voltage are identified that correlate with the arrhythmia substrate. Highly sensitive mapping techniques utilized during electrophysiological studies can unmask subtle, small-scale pathological areas that were undetectable pre-operatively, even with high-resolution imaging such as cardiac magnetic resonance (CMR). These findings mandate closer longitudinal follow-up and a re-evaluation of the patient’s long-term risk for arrhythmia recurrence or more severe adverse cardiovascular events.
Pre-Procedural Patient Preparation
Ablation for idiopathic ventricular tachycardia does not require extensive pre-operative preparation. General prerequisites include:
- Discontinuation of all antiarrhythmic medications for at least 5 days prior to the procedure.
- If the patient is receiving amiodarone, a significantly longer washout period (>20 days) is required due to its prolonged half-life.
- A detailed cardiovascular evaluation must be completed under medical supervision, primarily to rule out any underlying structural heart disease responsible for the arrhythmia.
- If the patient is on oral anticoagulants or antiplatelet therapy, management must be coordinated with the physician for peri-procedural guidance.
- Non-antiarrhythmic baseline medications may be continued normally, including on the day of the procedure.
- The patient must fast on the morning of the procedure (an evening meal the prior night is permitted); if the procedure is scheduled for the afternoon, a light breakfast is allowable.
- Upon admission, the patient must provide all prior diagnostic data, particularly historical 12-lead ECG recordings of the tachycardia.
Procedural Technique
The procedure is typically performed under local anesthesia at the access sites without general anesthesia. Deep sedation is utilized if the patient does not tolerate the procedure.
In the electrophysiology laboratory, the patient is connected to continuous ECG monitoring. Following local anesthesia, percutaneous femoral venous access is obtained to introduce vascular sheaths, through which electrophysiology catheters are advanced into specific intracardiac positions. Concurrently, a steerable mapping and ablation catheter is introduced. If the tachycardia focus is located in the right ventricle, the catheter is advanced via the femoral vein and inferior vena cava into the right atrium, crossing the tricuspid valve into the right ventricle. If the focus is located within the left ventricle or the aortic root, the catheter is introduced arterially via the femoral artery and advanced retrogradely across the aorta into the left ventricular cavity. A transseptal approach to the left ventricle via a femoral venous interatrial septal puncture can also be utilized. In rare instances, access via the coronary sinus and coronary veins or an epicardial approach is required.
Intracardiac signals are recorded and processed by 3D electroanatomical mapping systems, enabling real-time catheter visualization and navigation without continuous fluoroscopic radiation. The 3D system reconstructs a detailed activation map to localize the precise origin of the tachycardia for targeted energy delivery.
A common challenge during ablation of idiopathic ventricular tachycardias or premature ventricular contractions (PVCs) is the intraoperative suppression or absence of the arrhythmia, hindering detailed mapping. This issue is mitigated by selecting patients with a high baseline arrhythmic burden and employing intraoperative provocative maneuvers (e.g., intravenous isoproterenol infusion to facilitate arrhythmia induction, or pace-mapping techniques).
The procedural endpoint is the elimination of all ectopy originating from the target focus. If non-inducibility persists for approximately 30 minutes following the final energy application, the procedure is concluded. Hemostasis is achieved at the vascular access sites, and the patient is transferred to the recovery area prior to returning to the ward.
Pulsed Field Ablation (PFA) has also been developed for idiopathic ventricular arrhythmias, demonstrating favorable clinical outcomes.
Post-Procedural Care
Post-operatively, the patient returns to the ward and remains on strict bed rest, avoiding lower extremity movement during the initial hours. Mobilization occurs later that day or the following morning. A next-morning 12-lead ECG is obtained, and the patient is discharged with explicit instructions. Normal physical activities can be resumed on the second post-operative day. Longitudinal follow-up with periodic clinical assessments or Holter monitoring is required to evaluate for arrhythmia recurrence, particularly if baseline symptoms return.
Expected Outcomes
The expected clinical outcome, achieved in over 85% of cases, is the complete eradication of ventricular tachycardia episodes and all associated ectopy (e.g., PVCs or ventricular couplets) originating from the ablated focus. Despite an initial successful procedural endpoint, a 10–20% recurrence rate of the arrhythmic phenomena exists. Recurrence typically occurs due to tissue healing and recovery of the ablated myocardium, leading to resumption of automaticity or conduction within the arrhythmogenic focus. In the event of recurrence, a repeat ablation procedure can be performed.
Risks and Complications
Catheter ablation for idiopathic ventricular tachycardia carries a significantly higher safety profile compared to ablation in the setting of structural heart disease. The complication rate is comparable to that of supraventricular tachycardia ablations, occurring in approximately 3% of cases.
Potential complications include:
- Hematoma at the vascular access sites.
- Cardiac tamponade: Defined as blood accumulation within the pericardial space. It is a rare complication in this specific setting. It represents an acute medical emergency requiring immediate pericardiocentesis and drainage. A small pericardial drain remains for approximately 24 hours under close inpatient surveillance, typically extending hospital stay by 2–4 days.
- Atrioventricular (AV) block: Typically results from inadvertent energy delivery to the His-Purkinje system when the arrhythmogenic focus is located in close anatomical proximity to the conduction bundle.
- Thromboembolic events.
- Coronary artery injury secondary to catheter manipulation (sporadic reports).
Ventricular Tachycardia Ablation in Patients with Inherited Arrhythmia Syndromes
Catheter ablation does not constitute a first-line therapy of choice for ventricular tachycardias in this patient population. Ventricular tachycardias arising from inherited arrhythmogenic substrates are managed via alternate therapeutic modalities (see Inherited Arrhythmia Syndromes). Catheter ablation is reserved as a final therapeutic option for highly refractory ventricular tachycardias when all other medical and device interventions have failed.